Prevalence of visual field loss following exposure to vigabatrin therapy: A systematic review

Epilepsia

Volumn 51, Issue 12, 2010, Pages 2423-2431

  Maguire, Melissa J ^a   Hemming, Karla ^b   Wild, John M ^c   Hutton, Jane L ^d   Marson, Anthony G ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b CARDIFF UNIVERSITY   (United Kingdom)

^c UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^d UNIVERSITY OF WARWICK   (United Kingdom)

Author keywords

Prevalence studies; Vigabatrin; Visual field loss

Indexed keywords

ANTICONVULSIVE AGENT; VIGABATRIN;

AGE; ANTICONVULSANT THERAPY; ARTICLE; DISEASE DURATION; DOSE RESPONSE; DRUG EXPOSURE; DRUG SAFETY; FOCAL EPILEPSY; GENDER; HUMAN; PREVALENCE; PRIORITY JOURNAL; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; SYSTEMATIC REVIEW; TREATMENT DURATION; VISUAL FIELD DEFECT; VISUAL FIELD LOSS;

ADULT; ANTICONVULSANTS; CHILD; DRUG RESISTANCE; EPILEPSIES, PARTIAL; FEMALE; HUMANS; MALE; PREVALENCE; RISK; VIGABATRIN; VISION DISORDERS; VISUAL FIELD TESTS; VISUAL FIELDS;

EID: 78650020077     PISSN: 00139580     EISSN: 15281167     Source Type: Journal    
DOI: 10.1111/j.1528-1167.2010.02772.x     Document Type: Article

References (63)

1. Arndt CF, Derambure P, Defoort-Dhellemmes S, Hache JC. (1999) Outer retinal dysfunction in patients treated with vigabatrin. Neurology 52: 1201-1205.
2. Ascaso FJ, Lopez MJ, Mauri JA, Cristobal JA. (2003) Visual field defects in pediatric patients on vigabatrin monotherapy. Doc Ophthalmol 107: 127-130.
3. Brodie JD, Case BG, Figueroa E, Dewey SL, Robinson JA, Wanderling JA, Laska EM. (2009) Randomized, Double-Blind, Placebo-Controlled Trial of Vigabatrin for the Treatment of Cocaine Dependence in Mexican Parolees. Am J Psychiatry 166: 1269-1277.
4. Daneshvar H, Racette L, Coupland SG, Kertes PJ, Guberman A, Zackon D. (1999) Symptomatic and asymptomatic visual loss in patients taking vigabatrin. Opthalmology 106: 1792-1798.
5. DeToledo JC, Westall CA, Collins SD. (2006) Vigabatrin induced visual fields defects: update 2006. American Epilepsy Society Annual Meeting, December 1-5, Abstract 585 (poster).
6. Egger M, Davey Smith G, Schneider M, Minder C. (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315: 629-634.
7. Eke T, Talbot JF, Lawden MC. (1997) Severe persistent visual field constriction associated with vigabatrin. BMJ 314: 180-181.
8. Gaily E, Jonsson H, Lappi M. (2006) Visual fields in children treated with vigabatrin in infancy. American Epilepsy Society Annual Meeting, December 1-5, Abstract 2.176
9. Giordano L, Valseriati D, Vignoli A, Morescalchi F, Gandolfo E. (2000) Another case of reversibility of visual-field defect induced by vigabatrin monotherapy: is young age a favourable factor? Neurol Sci 21: 185-186.
10. Grant SM, Heel RC. (1991) Vigabatrin: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in epilepsy and disorders of motor control. Drugs 41: 889-926.
11. Gross-Tsur V, Banin E, Shahar E, Shalev RS, Lahat E. (2000) Visual impairment in children with epilepsy treated with vigabatrin. Ann Neurol 48: 60-64.
12. Hancock E, Osbourne J, Milner P. (2008) Treatment of infantile spasms. Cochrane Database Syst Rev 4: CD001770.
13. Hardus P, Verduin WM, Postma G, Stilma JS, Berendschot TT, Van Veelen CW. (2000) Concentric contraction of the visual field in patients with temporal lobe epilepsy and its association with the use of vigabatrin medication. Epilepsia 41: 581-587.
14. Hardus P, Verduin WM, Engelsman M. (2001) Visual field loss associated with vigabatrin: quantification and relation to dosage. Epilepsia 42: 262-267.
15. Hemming K, Maguire MJ, Hutton JL, Marson AG. (2008) Vigabatrin in refractory epilepsy. Cochrane Database Syst Rev 3: CD007302.
16. Hui AC, Liu DT, Wong KK, Man BL, Leung T, Lam PT, Lam DS. (2008) Vigabatrin-induced visual dysfunction in Chinese patients with refractory epilepsy. Eur J Ophthalmol 18: 624-627.
17. Iannetti P, Spalice A, Perla FM, Conicella E, Raucci U, Bizzarri B. (2000) Visual field constriction in children with epilepsy on vigabatrin treatment. Pediatrics 106: 838-842.
18. Jensen H, Sjö O, Uldall P, Gram L. (2002) Vigabatrin and retinal changes. Doc Ophthalmol 104: 171-180.
19. Johnson MA, Krauss GL, Miller NR. (2000) Visual function loss from vigabatrin: effect of stopping the drug. Neurology 55: 40-45.
20. Kalviainen R, Nousiainen I, Mantyjarvi M, Nikoskelainen E, Partanen J, Partanen K, Riekkinen P Sr., (1999) Vigabatrin, a GABAergic antiepileptic drug causes concentric visual field defects. Neurology 53: 922-932.
21. Kinirions P, Cavalleri GL, Singh R, Shahwan A, Acheson J, Wood NW, Goldstein DB, Sisodiya SM, Doherty CP, Delanty N. (2006a) A Pharmacogenetic exploration of vigabatrin induced visual field constriction. Epil Res 70: 144-152.
22. Kinirons P, Cavalleri GL, O'Rouke D, Doherty CP, Reid I, Logan P, Liggan B, Delanty N. (2006b) Vigabatrin retinopathy in an Irish cohort: lack of correlation with dose. Epilepsia 47: 311-317.
23. Kiratli H, Türkçüoǧlu P, (2001) Rapid development of visual field defects associated with vigabatrin therapy. Eye. 15 (Pt 5): 672-674.
24. Krakow K, Polizzi G, Riordan-Eva P, Holder G, MacLeod WN, Fish DR. (2000) Recovery of visual field constriction following discontinuation of vigabatrin. Seizure 9: 287-290.
25. Krauss GL, Johnson MA, Miller NR. (1998) Vigabatrin-associated retinal cone system dysfunction: electroretinogram and ophthalmologic findings. Neurology 50: 614-618.
26. Lawden MC, Eke T, Degg C, Harding GFA, Wild JM. (1999) Visual field defects associated with vigabatrin therapy. J Neurol Neurosurg Psychiatry 67: 716-722.
27. Lawthom C, Smith PE, Wild JM. (2009) Nasal retinal nerve fiber layer attenuation: a biomarker for vigabatrin toxicity. Ophthalmology 116: 565-571.
28. Leach JP, Rao P, Ahlfat F, Kyle G, Chadwick DW. (1998) Vigabatrin and visual filed defects: is there a link? Epilepsia 39 (suppl 6): 58.
29. Lhatoo SD, Sander JW. (1999) Infantile spasms and vigabatrin: visual field defects may be permanent. BMJ 318: 57.
30. Lux AL, Edwards SW, Hancock E, Johnson AL, Kennedy CR, Newton RW, O'Callaghan FJ, Verity CM, Osbourne JP. (2004) The United Kingdom Infantile Spasms Study comparing vigabatrin with prednisolone or tetracosactide at 14 days: a multicentre, randomised controlled trial. Lancet 364: 1173-1178.
31. Malmgren K, Ben-Menachem E, Frisén L. (2001) Vigabatrin visual toxicity: evolution and dose dependence. Epilepsia 42: 609-615.
32. Manuchehri K, Goodman S, Siviter L, Nightingale S. (2000) A controlled study of vigabatrin and visual abnormalities. Br J Ophthalmol 84: 499-505.
33. Marson AG, Kadir ZA, Hutton JL, Chadwick DW. (1997) The new antiepileptic drugs: a systematic review of their efficacy and tolerability. Epilepsia 38: 859-880.
34. Mauri-Llerda JA, Iñiguez C, Tejero-Juste C, Santos-Lasaosa S, Escalza-Cortina I, Ascaso-Puyuelo J, Abad-Alegría F, Morales-Asín F. (2000) Visual field changes secondary to vigabatrin treatment. Rev Neurol 31: 1104-1108.
35. McDonagh J, Stephen LJ, Dolan FM, Parks S, Dutton GN, Kelly K, Keating D, Sills GJ, Brodie MJ. (2003) Peripheral retinal dysfunction in patients taking vigabatrin. Neurology 61: 1690-1694.
36. Midelfart A, Midelfart E, Brodtkorb E. (2000) Visual field defects in patients taking vigabatrin. Acta Ophthalmol Scand 78: 580-584.
37. Miller NR, Johnson MA, Paul SR, Girkin CA, Perry JD, Endres M, Krauss GL. (1999) Visual dysfunction in patients receiving vigabatrin: clinical and electrophysiologic findings. Neurology 53: 2082-2087.
38. Moreno MC, Giagante B, Saidon P, Kochen S, Benozzi J, Rosenstein RE. (2005) Visual defects associated with vigabatrin: a study of epileptic argentine patients. Can J Sci 32: 459-464.
39. Newman WD, Tocher K, Acheson JF. (2002) Vigabatrin associated visual field loss: a clinical audit to study prevalence, drug history and effects of drug withdrawal. Eye 16: 567-571.
40. Nicolson A, Leach JP, Chadwick DW, Smith DF. (2002) The legacy of vigabatrin in a regional epilepsy clinic. J Neurol Neurosurg Psychiatry 73: 327-329.
41. Nousiainen I, Mäntyjärvi M, Kälviäinen R. (2001) No reversion in vigabatrin-associated visual field defects. Neurology 57: 1916-1917.
42. Paul SR, Krauss GL, Miller NR, Medura MT, Miller TA, Johnson MA. (2001) Visual function is stable in patients who continue long-term vigabatrin therapy: implications for clinical decision making. Epilepsia 42: 525-530.
43. Pelosse B, Momtchilova M, Roubergue A, Doummar D, Billette de Villemeur T, Laroche L. (2001) Etude du champ visuel et traitement par vigabatrin chez I'enfant. J Fr Ophthalmol 24: 1075-1080.
44. Pojda-Wilczek D, Emich-Widera E, Herba E, Pojda SM, Marszat E. (2005) The function of eye and vision system in children and youth treated with vigabatrin: our own experience. Klin Oczna 107: 654-657.
45. Riise P, Fledelius HC, Rogvi-Hansen B. (2003) Vigabatrin og synsfeltdefekter. Ugeskr Laeger 165: 1034.
46. Rintahaka P, Granström ML, Lappi M. (2000) Visual field defects in vigabatrin-treated children with epilepsy. Epilepsia 41 (suppl 7): 196-197.
47. Roccella M, Parisi L, D'Iapico N. (2001) Analisi del campo visivo nei bambini con epilessia parziale in monoterapia con Vigabatrin. Boll Lega It Epil 113-114:243-244.
48. Russell-Eggitt IM, Mackey DA, Taylor DS, Timms C, Walker JW. (2000) Vigabatrin associated visual field defects in children. Eye. 14 (Pt 3A): 334-339.
49. Schechter PJ. (1989) Clinical pharmacology of vigabatrin. Br J Clin Pharmacol 27 (suppl 1): 19S-22S.
50. Schmitz B, Schmidt T, Jokiel B, Pfeiffer S, Tiel-Wilck K, Rüther K. (2002) Visual field constriction in epilepsy patients treated with vigabatrin and other antiepileptic drugs: a prospective study. J Neurol 249: 469-475.
51. Specchio LM, Bellizzi M, La Neve A. (2000) Visual impairment in adult epileptic patients treated with vigabatrin. Neurology 54 (suppl 3): A308.
52. Toggweiler S, Weiser H. (2001) Concentric visual field restriction under vigabatrin therapy: extent depends on the duration of the drug intake. Seizure 10: 420-423.
53. Tseng YL, Lan MY, Lai S, Huang F, Tsai J. (2006) Vigabatrin-attributable visual field defects in patients with intractable partial epilepsy. Acta Neurol Taiwan 15: 244-250.
54. Van Der Torren K, Graniewski-wijnands HS, Polak BCP. (2002) Visual field and electrophysiological abnormalities due to vigabatrin. Doc Ophthalmol 104: 181-188.
55. Vanhatalo S, Nouisiainen I, Eriksson K, Rantala H, Vainionpaa L, Mustonen K, Aarimaa T, Alen R, Aine M, Byring R, Hirvasniemi A, Nuutila A, Walden T, Ritanen-Mohammed U, Karttunen-Lewandowski P, Pohjola L, Kaksonen S, Jurvelin P, Granstrom M. (2002) Visual field constriction in 91 Finnish children treated with vigabatrin. Epilepsia 43: 748-756.
56. Virgilio GD, Gens H, Luzeiro I. (2002) Visual field defects and vigabatrin. Epilepsia 43 (suppl 8): 151.
57. Werth R, Schadler G. (2006) Visual field loss in young children and mentally handicapped adolescents receiving vigabatrin. Invest Ophthalmol Vis Sci 47: 3028-3035.
58. Wild JM, Martinez C, Reinshagen G, Harding GF. (1999) Characteristics of a unique visual field defect attributed to vigabatrin. Epilepsia 40: 1784-1794.
59. Wild JM, Robson CR, Jones AL, Cunliffe IA, Smith PE. (2006) Detecting vigabatrin toxicity by imaging of the retinal nerve fiber layer. Invest Ophthalmol Vis Sci 47: 917-924.
60. Wild JM, Chiron C, Ahn H, Baulac M, Bursztyn J, Gandolfo E, Goldberg I, Goñi FJ, Mercier F, Nordmann JP, Safran AB, Schiefer U, Perucca E. (2009) Visual field loss in patients with refractory partial epilepsy treated with vigabatrin: final results from an open-label, observational, multicentre study. CNS Drugs 23: 965-982.
61. Wilton LV, Stephens MD, Mann RD. (1999) Visual field defect associated with vigabatrin: observational cohort study. BMJ 319: 1165-1166.
62. Wohlrab G, Boltshauser E, Schmitt B, Schriever S, Landau K. (1999) Visual field constriction is not limited to children treated with vigabatrin. Neuropediatrics 30: 130-132.
63. You SJ, Ahn HS, Ko TS. (2006) Vigabatrin and visual field defects in paediatric patients. J Korean Med Sci 21: 728-732.